March 10, 2025 – Boston, MA – Beam Therapeutics has announced positive early results from a Phase 1/2 trial of BEAM-302, a gene therapy designed to treat Alpha-1 Antitrypsin Deficiency (AATD), a genetic disease that affects the lungs and liver. The study, which included nine patients so far, found that the therapy increased functional protein levels while maintaining a strong safety profile.
What is Alpha-1 Antitrypsin Deficiency (AATD)?
AATD is a genetic disorder caused by a mutation in the SERPINA1 gene, which leads to a shortage of Alpha-1 Antitrypsin (AAT). Without enough AAT, patients can experience lung damage (chronic cough, shortness of breath) and liver complications (jaundice, vomiting blood).
BEAM-302 uses CRISPR gene editing to precisely correct the mutation responsible for AATD, offering a potential one-time treatment.
Key Findings from the Trial
- Nine patients received a single intravenous infusion of BEAM-302 at doses of 15 mg, 30 mg, or 60 mg.
- No serious adverse events were reported.
- All adverse events were mild or moderate, with no dose-limiting toxicities.
- Patients receiving higher doses had higher increases in functional AAT:
- 15 mg dose: 1.6x increase
- 30 mg dose: 1.9x increase
- 60 mg dose: 2.8x increase (exceeding the therapeutic threshold)
- Beam plans to test a higher dose in future studies to determine if further improvements can be made.
How BEAM-302 Stands Out
Unlike other gene therapies that attempt to knock out dysfunctional genes, BEAM-302 corrects the genetic mutation, making it a potentially permanent solution. Competing treatments, like Wave’s WVE-006, require ongoing dosing, while BEAM-302 aims to be a one-time fix.
What Experts Are Saying
“This is the first clinical evidence of precise gene correction for a disease-causing mutation,” said John Evans, CEO of Beam Therapeutics. “The results suggest that a simple IV infusion could transform treatment for AATD patients.”
What’s Next for BEAM-302?
- A fourth dose cohort will be added to the trial to explore even higher levels of AAT correction.
- More data will be presented at a medical conference later this year.
- The trial will expand to include patients with both lung and liver involvement.
Beam Therapeutics continues to push the boundaries of gene editing and could be on the verge of delivering a breakthrough treatment for a previously untreatable genetic disease.
For further updates, visit www.beamtx.com.